跳到正文
原文
medRxiv 预印本· Wang, C., Paul, R., Li, Y., Smith, S., Cao, Q., Chang, S. H., Charlab, R., Coroller, T., Huang, R., Amiri-Kordestani, L., Li, Z., Liu, Q., Osgood, C., Peyrard, S., Sahiner, B., Santana-Quintero, L., Su, F., Zarate, J. P., Zhu, H., Ohlssen, D., Petrick, N., Amatya, A., Solovieff, N. ·· 2026-10-13AI 评分38

基于多模态机器学习的MONALEESA试验HR+/HER2-转移性乳腺癌PFS预后因素分析

Multimodal Machine Learning-Based Clinical and Genomic Prognostic Factors for Progression-Free Survival in Metastatic Breast Cancer Using Phase III MONALEESA Trials

AI 导读

诺华与FDA合作,利用III期MONALEESA-2、-3、-7试验数据构建多模态机器学习模型,预测HR+/HER2-晚期乳腺癌患者无进展生存期。晚期融合模型预后性能最优(C-index 0.727,95% CI 0.641-0.799),风险分层识别出低危与高危组(PFS HR 0.28,95% CI 0.20-0.38)。

来源:medRxiv 预印本 · medrxiv.org